A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson’s disease

Kallol Ray Chaudhuri; Antoniya Todorova; Melissa Nirenberg; Miriam Parry; Anne Martin; Pablo Martinez-Martin; Alexandra Rizos; Tove Henriksen; Jost Wolfgang; Alexander Storch; Heinz Reichmann; Georg Ebersbach; Per Odin; Angelo Antonini

doi:10.1002/mdc3.12141

A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson’s disease

Kallol Ray Chaudhuri, Antoniya Todorova, Melissa Nirenberg, Miriam Parry, Anne Martin, Pablo Martinez-Martin, Alexandra Rizos, Tove Henriksen, Jost Wolfgang, Alexander Storch, Heinz Reichmann, Georg Ebersbach, Per Odin, Angelo Antonini

Basic and Clinical Neuroscience

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

1 Downloads (Pure)

Abstract

Dopamine agonist withdrawal syndrome (DAWS) has been reported in patients with Parkinson's disease (PD) who rapidly decrease or stop their dopamine agonist (DA) treatment. Retrospective studies suggest a high prevalence of DAWS (14%–18%) in PD, but there are no prospective studies. We report data from the first pilot European multicenter prospective study addressing the frequency of probable DAWS (Rabinak-Nirenberg criteria) in PD patients. The self-completed Nonmotor Symptoms Questionnaire (which addresses the core features of DAWS) was administered at clinical follow-up at 1 month in 51 patients (33 male; mean age: 73.0 ± 9.9 years; PD duration: 12.2 ± 6.3 years) who had discontinued dopamine agonists. Twelve out of fifty-one patients (24%) met clinical criteria for DAWS, the most common symptoms of which were anxiety (91.7%), pain (50%), sweating (41.7%), and anhedonia (16.7%), after the withdrawal of a DA (ropinirole, pramipexole, or cabergoline). In this first prospective evaluation of DAWS in the clinic, preliminary data indicate a high rate after discontinuation of a range of DAs, particularly in the context of impulse control disorders. Larger, controlled studies are required to establish a definitive management pathway.

Original language	English
Number of pages	5
Journal	Movement Disorders Clinical Practice
DOIs	https://doi.org/10.1002/mdc3.12141
Publication status	E-pub ahead of print - 2015

Keywords

DAWS
Parkinson's disease

Access to Document

10.1002/mdc3.12141

Cite this

Ray Chaudhuri, K., Todorova, A., Nirenberg, M., Parry, M., Martin, A., Martinez-Martin, P., Rizos, A., Henriksen, T., Wolfgang, J., Storch, A., Reichmann, H., Ebersbach, G., Odin, P., & Antonini, A. (2015). A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson’s disease. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.12141

@article{42df5c8e62cd452c8dd8bf2cca45ecf8,

title = "A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson{\textquoteright}s disease",

abstract = "Dopamine agonist withdrawal syndrome (DAWS) has been reported in patients with Parkinson's disease (PD) who rapidly decrease or stop their dopamine agonist (DA) treatment. Retrospective studies suggest a high prevalence of DAWS (14%–18%) in PD, but there are no prospective studies. We report data from the first pilot European multicenter prospective study addressing the frequency of probable DAWS (Rabinak-Nirenberg criteria) in PD patients. The self-completed Nonmotor Symptoms Questionnaire (which addresses the core features of DAWS) was administered at clinical follow-up at 1 month in 51 patients (33 male; mean age: 73.0 ± 9.9 years; PD duration: 12.2 ± 6.3 years) who had discontinued dopamine agonists. Twelve out of fifty-one patients (24%) met clinical criteria for DAWS, the most common symptoms of which were anxiety (91.7%), pain (50%), sweating (41.7%), and anhedonia (16.7%), after the withdrawal of a DA (ropinirole, pramipexole, or cabergoline). In this first prospective evaluation of DAWS in the clinic, preliminary data indicate a high rate after discontinuation of a range of DAs, particularly in the context of impulse control disorders. Larger, controlled studies are required to establish a definitive management pathway.",

keywords = "DAWS, Parkinson's disease",

author = "{Ray Chaudhuri}, Kallol and Antoniya Todorova and Melissa Nirenberg and Miriam Parry and Anne Martin and Pablo Martinez-Martin and Alexandra Rizos and Tove Henriksen and Jost Wolfgang and Alexander Storch and Heinz Reichmann and Georg Ebersbach and Per Odin and Angelo Antonini",

year = "2015",

doi = "10.1002/mdc3.12141",

language = "English",

journal = "Movement Disorders Clinical Practice",

issn = "2330-1619",

publisher = "Wiley-Blackwell",

}

Ray Chaudhuri, K, Todorova, A, Nirenberg, M, Parry, M, Martin, A, Martinez-Martin, P, Rizos, A, Henriksen, T, Wolfgang, J, Storch, A, Reichmann, H, Ebersbach, G, Odin, P & Antonini, A 2015, 'A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson’s disease', Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.12141

TY - JOUR

T1 - A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson’s disease

AU - Ray Chaudhuri, Kallol

AU - Todorova, Antoniya

AU - Nirenberg, Melissa

AU - Parry, Miriam

AU - Martin, Anne

AU - Martinez-Martin, Pablo

AU - Rizos, Alexandra

AU - Henriksen, Tove

AU - Wolfgang, Jost

AU - Storch, Alexander

AU - Reichmann, Heinz

AU - Ebersbach, Georg

AU - Odin, Per

AU - Antonini, Angelo

PY - 2015

Y1 - 2015

N2 - Dopamine agonist withdrawal syndrome (DAWS) has been reported in patients with Parkinson's disease (PD) who rapidly decrease or stop their dopamine agonist (DA) treatment. Retrospective studies suggest a high prevalence of DAWS (14%–18%) in PD, but there are no prospective studies. We report data from the first pilot European multicenter prospective study addressing the frequency of probable DAWS (Rabinak-Nirenberg criteria) in PD patients. The self-completed Nonmotor Symptoms Questionnaire (which addresses the core features of DAWS) was administered at clinical follow-up at 1 month in 51 patients (33 male; mean age: 73.0 ± 9.9 years; PD duration: 12.2 ± 6.3 years) who had discontinued dopamine agonists. Twelve out of fifty-one patients (24%) met clinical criteria for DAWS, the most common symptoms of which were anxiety (91.7%), pain (50%), sweating (41.7%), and anhedonia (16.7%), after the withdrawal of a DA (ropinirole, pramipexole, or cabergoline). In this first prospective evaluation of DAWS in the clinic, preliminary data indicate a high rate after discontinuation of a range of DAs, particularly in the context of impulse control disorders. Larger, controlled studies are required to establish a definitive management pathway.

AB - Dopamine agonist withdrawal syndrome (DAWS) has been reported in patients with Parkinson's disease (PD) who rapidly decrease or stop their dopamine agonist (DA) treatment. Retrospective studies suggest a high prevalence of DAWS (14%–18%) in PD, but there are no prospective studies. We report data from the first pilot European multicenter prospective study addressing the frequency of probable DAWS (Rabinak-Nirenberg criteria) in PD patients. The self-completed Nonmotor Symptoms Questionnaire (which addresses the core features of DAWS) was administered at clinical follow-up at 1 month in 51 patients (33 male; mean age: 73.0 ± 9.9 years; PD duration: 12.2 ± 6.3 years) who had discontinued dopamine agonists. Twelve out of fifty-one patients (24%) met clinical criteria for DAWS, the most common symptoms of which were anxiety (91.7%), pain (50%), sweating (41.7%), and anhedonia (16.7%), after the withdrawal of a DA (ropinirole, pramipexole, or cabergoline). In this first prospective evaluation of DAWS in the clinic, preliminary data indicate a high rate after discontinuation of a range of DAs, particularly in the context of impulse control disorders. Larger, controlled studies are required to establish a definitive management pathway.

KW - DAWS

KW - Parkinson's disease

U2 - 10.1002/mdc3.12141

DO - 10.1002/mdc3.12141

M3 - Article

SN - 2330-1619

JO - Movement Disorders Clinical Practice

JF - Movement Disorders Clinical Practice

ER -

A pilot prospective, multicenter observational study of dopamine agonist withdrawal syndrome in Parkinson’s disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this